Mergers and Acquisitions

The acquisition of biopharmaceutical company TESARO is expected to strengthen GSK’s oncology pipeline and commercial footprint.

The $8-billion acquisition will broaden Lilly's oncology portfolio in precision medicines and treatments that target cancers caused by specific gene abnormalities.

The $252-million acquisition is expected to strengthen Cambrex’s position as a small-molecule CDMO across the drug lifecycle.

Merger cites combined strengths in oncology, immunology and inflammation, and cardiovascular disease.

The $2.1-billion acquisition strengthens Novartis’ position in nuclear medicine and radioligand therapy for treating cancer.

The proposed $12.7-billion deal includes the spinoff of GSK and Pfizer consumer brands to a new UK-listed company.

Roquette has announced the completion of its acquisition of a majority stake in a pharma packaging company based in India.

Capital Recovery Group, Federal Equipment Company, Heritage Global Partners, and PPL Group purchased a 110-acre campus with a flexible pharmaceutical manufacturing and packaging facility from a generics manufacturer in Huntsville, AL.

The merged companies will provide histopathology services in the research and pre-clinical therapeutics markets.

The $62-billion acquisition of Shire by Takeda Pharmaceutical was approved by both sets of shareholders.

GSK and TESARO have entered into a definitive agreement concerning GSK's acquisition of TESARO for an aggregate cash consideration worth approximately $5.1 billion.

The acquisition will give Genentech full rights to Jecure’s preclinical portfolio of NLRP3 inhibitors.

With the $252-million acquisition of contract development, manufacturing, and testing organization Avista Pharma Solutions, Cambrex will enter the market for early stage small-molecule development and testing services.

Ardena has moved into its expanded headquarters, located in Gent, Belgium, as a result of continued growth.

he acquisition expands the company’s formulation and analytical R&D services.

Novartis plans to acquire Endocyte, a biopharmaceutical company, to accelerate the development of innovative radioligand technology for treating cancer.

Roche has acquired Tusk Therapeutics in a deal worth up to EUR 659 million (US$762 million).

The company’s three acquisitions over the last 12 months have increased its global presence, expanding its European footprint and bringing new localized services in Asia-Pacific and the west coast of the United States.

The divestiture of the European generic-drug business of Sanofi-Zentiva-to Advent International has been completed.

The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Becton Dickinson’s (BD) Advanced Bioprocessing business will be integrated into Thermo Fisher's Life Sciences Solutions segment.

Emergent BioSolutions is set to acquire Adapt Pharma, a pharmaceutical company focused on addressing the opioid overdose and addiction crisis, in a deal worth up to $735 million.

Novartis will sell selected portions of its Sandoz United States portfolio to Aurobindo Pharma USA for $900 million in cash, plus $100 million in potential earn-outs.

Skin-focused company LEO Pharma acquired Bayer’s prescription treatment portfolio.

The acquisition strengthens Nelson Labs’ outsourced testing capabilities for the pharmaceutical and medical device industries.

The acquisition will support Novo Nordisk’s development of glucose-responsive insulins.

The acquisition will strengthen Astellas Pharma’s position in ophthalmology.

The combined companies will provide research- and clinical-grade human immune cells, blood products, and related services.

Denmark-headquartered pharmaceutical company LEO Pharma is set to acquire Bayer’s prescription treatment portfolio.

Stem-cell developer TiGenix has been acquired by Takeda Pharmaceutical for approximately EUR 520 million (US$604 million).